Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

Sugiura, K; Seo, Y; Takahashi, T; Tokura, H; Ito, Y; Tanaka, M; Kishida, N; Nishi, Y; Onishi, Y; Aoki, H

Seo, Y (corresponding author), Ashikaga Red Cross Hosp, 284-1 Yobe Cho, Ashikaga, Tochigi 3260843, Japan.

BMC GASTROENTEROLOGY, 2021; 21 (1):

Abstract

BackgroundTAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence support......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索